Rapid tests that are low-cost and portable are the first line of defence in healthcare systems. Dipstick and lateral-flow are the two universal assay formats as they are lightweight and compact, and provide qualitative results without external instrumentation. However, existing formats have limitations in the quantification of analyte concentrations. Hence, the demand for sample preparation, improved sensitivity and user-interface has challenged the commercial products. Recently, capabilities, sensors and readout devices were expanded to multiplexable assays platforms, which might transcend the capabilities of existing design format of diagnostic tests. This chapter outlines the evolution of diagnostic devices and current trends in the development of qualitative and quantitative sensing devices for applications in healthcare, veterinary medicine, environmental monitoring and food safety. The chapter also discusses design parameters for diagnostics, their functionalisation to increase the capabilities and the performance, emerging sensing platforms and readout technologies. The factors which limit the emerging rapid diagnostics to become commercial products are also discussed.

The life expectancy has grown worldwide, which also increased the healthcare spending [1, 2]. For example, 720 million people will be aged 65 or older by 2020. Currently four in five people over the age of 75 take at least one prescribed medicine, and this trend is set to increase [3]. For some of the medications, large pharma find it the hard to recover R&D costs while the pressure from the regulatory agencies also increased for the use of new drugs as the first line of defence based on efficacy and cost. Hence, the global healthcare trends and ever increasing pressure from regulatory agencies put a strong case for the development of diagnostics for healthcare monitoring as well as the evaluation of drug efficacies in clinical trials. All these considerations parallels governments’ and insurance companies’ interests in obtaining the best performance possible and treatment benefits they support. These trends are behind the driving force for the development of diagnostics that can reduce the healthcare costs by developing effective drugs and identifying diseases and conditions at an early stage.

The major stumbling block in monitoring and controlling diseases/contaminations remains delivering simple, low-cost and robust diagnostic tests [4, 5]. In the developing world, the basic healthcare infrastructure and trained healthcare personnel are
limited [6, 7]. Other trends include increase in healthcare associated infections [8, 9], preservation of the life span of cost-effective drugs [10], increase in spurious/counterfeit medicines [11], and mitigating the epidemic-to-pandemic transitions of infectious diseases [12]. In terms of impact, low-cost diagnostics will reach underserved communities. Low-cost diagnostics that can allow local communities in developing regions to improve healthcare [13], environmental safety [14], animal health [15, 16], and food quality [17] will play key roles in the United Nation’s Post-2015 Millennium Development Goals.

In the developing world, medical diagnostics for poverty-related conditions are outdated. In the absence of the diagnostic equipment, healthcare personnel make their decisions based on symptoms. WHO’s Integrated Management of Childhood Illness (IMCI) is a diagnosis guideline based on signs and symptoms with minimum or no instrumentation [18, 19]. However, such systematic guidelines have limitations in (i) distinguishing asymptomatic diseases, (ii) detecting multiple infections, (iii) identifying the disease window period, and (iv) quantifying concentrations of target analytes. Eventually, the development and delivery of affordable testing technologies can enable local communities that lack access to technical and human resources present in urban areas. The deficiency in diagnostics and healthcare resources can have an irreversible negative effect on developing economies. Such an economic impact is pronounced for non-infectious as well as infectious diseases. For example, the Ebola virus epidemic in West Africa has overwhelmed the healthcare systems of Liberia, Sierra Leone, Guinea and their neighbouring countries since 2013. Such outbreaks have a profound impact on the development of emerging economies. Currently, it is difficult to identify Ebola because its symptoms such as fever are generic, also seen in commonly occurring diseases such as malaria and typhoid fever. Existing laboratory techniques are based on transcription polymerase chain reaction (RT-PCR) and quantitative PCR; however, they are not portable and affordable in the developing world. Other rapid tests suffer from sensitivity and selectivity, which may put the entire healthcare system at risk by misdiagnosing patients. Yet, recent Ebola epidemic is an example of many ongoing difficulties in healthcare systems and highlights the dire need for the development of low-cost rapid diagnostics.

While the main application of rapid tests is in medical diagnostics, such assays are also necessary for veterinary testing, environmental monitoring and food quality testing. Low-cost diagnostics would allow farmers and entrepreneurs in the developing world to assess the quality of their products and mitigate potential risks due to enterohemorrhagic strain of *E. coli* (O157:H7) and *Salmonella* in undercooked meat and poultry products [17]. Low-cost diagnostics are also required in testing water supplies. Inadequate environmental monitoring capabilities were highlighted by the cholera epidemic in Haiti after the earthquake in 2010 [20–24]. Although the cholera epidemic took most people by surprise, it wasn’t totally unexpected since Haiti ranked last out of 147 countries surveyed in the 2002 Water Poverty Index [25]. Due to globalisation, such epidemics also concern the developed nations. The development of low-cost, rapid quantitative diagnostics will aid in screening large regions and populations. For the development of rapid
diagnostics, WHO has outlined a set of criteria corresponding to the acronym ASSURED: Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment free and Deliverable to those who need it [10]. For the developing world, the trend towards low-cost is a priority; however, clinically useful sensitivity and specificity from rapid diagnostics assays are also required. Operating with low-volume samples without manual manipulation, being portable and functioning without sharps such as needles are considered desirable characteristics of rapid assays. Hence, the development of robust diagnostic tests can enable individuals and local communities to monitor their health condition and timely mitigate the spread of diseases.

1.1 The Development of Rapid Diagnostics

Historical assay formats for point-of-care testing are dipsticks and lateral flow devices. In the 1950s, the earliest paper-based strip test emerged for the quantification of the concentration of glucose in urine, and this product was marketed in the 1960s [26]. The principle of operation of the assay was based on glucose oxidase, and developed colours were compared to a reference chart for interpretation. Today, commercial urinalysis strip tests are adapted for a wide range of analytes. Traditionally, these tests are semi-quantitatively read with a colorimetric chart or with detection equipment such as CLINITEK Status® + Analyzer (Siemens) or Urisys 1100® Urine Analyzer (Roche). In the 1950s, parallel to the development of strip tests, latex agglutination assays and radioimmunoassays were also developed [27, 28]. Since the 1970s, nitrocellulose matrices have been used as a substrate for molecular detection [29–31]. In the 1980s, serological lateral-flow tests emerged [32]. The most notable example is the human pregnancy test, which was derived from the development of hCG beta-subunit radioimmunoassay [33]. Since then, commercial rapid lateral flow assays expanded beyond clinical diagnostics to veterinary, food, environmental applications, bio-defence and drug abuse (Table 1.1). Rapid diagnostic tests often have lower specificity and sensitivity than their laboratory bench counterparts. The majority of these tests are simple and provide yes/no answer, where response time is critical to the user.

The commercial rapid tests have various geometries and configurations with/without housing units (Fig. 1.1). Figure 1.1d shows a multiplexed lateral-flow assay, which allows the analyses of a single sample simultaneously. Lateral-flow immunoassays have two major configurations: Direct (i.e. double antibody sandwich assays) and competitive (i.e. inhibitive) formats. The assay format typically consists of a number of segments: sample pad, conjugate pad, reaction membrane and an absorbent pad (Fig. 1.1e). These segments are supported by a backing card and enclosed in a plastic cassette (housing). Another format in rapid diagnostics is flow-through (vertical), which is relatively more complex than lateral flow format, and its execution requires (i) sample placement, (ii) washing and (iii) addition of analyte-colloidal gold conjugates [68] (Fig. 1.1f). Most of the commercial assays require sample preparation.
| Test | Application |
|------|-------------|
| **Urinalysis** | Metabolic disorders: Human chorionic gonadotropin (pregnancy) [34], (pH, glucose, protein, ketone, leukocytes, nitrite, blood, urobilinogen, bilirubin, specific gravity) [35–39], albumin to creatinine ratio [40, 41], and ascorbic acid [37, 39]  
Drug abuseb: Alcohol, amphetamines, barbiturates, benzodiazepines, buprenorphine, cocaine, ketamine, methamphetamines, methadone, morphine/opiates, oxycodone, phencyclidine, propoxyphene, 9-tetrahydrocannabinol (marijuana), and tricyclic antidepressants [42–45] |
| **Immuoassays** | Infectious diseases: *C. difficile*, *Cytomegalovirus*, dengue fever, *E. coli*, enterics, epstein barr virus, mononucleosis, giardiasis, herpes simplex virus, HIV, Lyme disease, malaria, measles, *S. aureus*, methicillin-resistant *Staphylococcus aureus* (MRSA), mumps, rubella, syphilis, toxoplasmosis, tuberculosis, varicella zoster, West Nile virus, hepatitis B/C, Chagas disease, *chlamydia*, cholera, hantavirus, leishmaniasis, leptospirosis, *Listeria*, and *H. pylori* [46–50]  
Respiratory diseases: Influenza (flu), Legionnaire’s disease, pneumonia, respiratory syncytial virus, streptococcal pharyngitis, and *Streptococcus pneumoniae* [46–48, 50]  
Cardiovascular condition: acute kidney injury, acute coronary syndrome, cystipidemia, heart failure, oral anticoagulation, shortness of breath, and venous thrombosis [46]  
Oncology: Bladder, colon cancer, and colorectal cancer [46, 48]  
Women’s health: Osteoporosis, ovulation, and preeclampsia [46]  
**Veterinary diagnostics** | Canine: Blood, urobilinogen, bilirubin, protein, nitrite, ketones, glucose, pH, density, leukocytes, heartworm (*Dirofilaria immitis*), parvovirus, *Giardia*, Lyme disease, distemper virus, *coronavirus*, *Ehrlichia*, *Leishmania*, adenovirus, rotavirus, pancreatic lipase, relaxin, blood group typing, *Borrelia*, *Brucella*, c-reactive protein, *Leptospira*, progesterone, rabies, rheumatoid factor, and vaccination status [51–54]  
Feline: Blood, urobilinogen, bilirubin, protein, nitrite, ketones, glucose, pH, density, leukocytes, immunodeficiency virus, leukemia virus, heartworm (*Dirofilaria immitis*), *Ehrlichia*, *Leishmania*, *Giardia*, parvovirus, infectious peritonitis, *Toxoplasma gondii*, relaxin, blood group typing, *Borrelia*, *chlamydia*, coronavirus, panleukopenia, progesterone, and vaccination status [51, 53, 54]  
Bovine: Alpha toxin, *Brucella*, *Chlamydophila*, *Clostridium perfringens*, coronavirus, *Cryptosporidium*, rotavirus, *E. coli* K99, *Crypto-sporidium parvum*, epsilon toxin, foot-and-mouth disease virus, IgG, *Leptospira*, *Mycobacterium bovis*, *Neospora*, progesterone, rabies, parainfluenza-3, and rotavirus [53]  
Swine: Aujeszky’s disease, *Clostridium perfringens*, *Cryptosporidium*, epidemic diarrhea virus, rotavirus, alpha toxin, foot-and-mouth disease virus, progesterone, and transmissible gastroenteritis virus [53] |

(continued)
Table 1.1 (continued)

| Test                                      | Application                                                                 |
|-------------------------------------------|-----------------------------------------------------------------------------|
| **Equine:**                               | *Borrelia*, rotavirus, *Clostridium perfringens*, IgG, pregnant mare serum gonadotropin, progesterone, tetanus, and troponin [53] |
| **Avian:**                                | Influenza, *Chlamydophila*, infectious bursal disease, and Newcastle disease [53] |
| **Small ruminants:**                      | Foot-and-mouth disease virus [53]                                           |
| **Food and beverage safety tests**        | Mycotoxins: Afatoxins, deoxynivalenol (vomitoxin), fumonisins, zearalenone, ochratoxin, T-2 and HT-2 toxin, patulin, ergot alkaloids [55–58] |
| **Food pathogens:**                       | *E.Coli* O157:H7, *Listeria*, *Staphylococcus aureus*, and *Salmonella Enteritidis* [55–58] |
| **Food allergens:**                       | Almond, brazil nut, casein, cashew/pistachio, coconut, hazelnut, lupin, macadamia nut, mustard, peanut, sesame, soy, walnut, whole egg, β-lactoglobulin, total milk, crustacea, and gliadin/gluten [55, 56] |
| **Genetically modified organisms:**       | Bulk grain, seed and leaf, toasted meal, and corn Comb 7 Traits [55]       |
| **Veterinary drug residues:**             | Chloramphenicol, nitrofuran AMOZ/AOZ/AHD, clenbuterol, ractopamine, beta agonists, dexamethasone, ciprofloxacin, quinolones, β-Lactam antibiotics, florinax, aminoglycoside, amphenicol, enrofloxacin, macrolide, sulphonomide, tetracycline, and melamine [55–57] |
| **Beverage:**                             | Methanol contamination, acetic acid, citric acid, D-glucose, D-fructose, lactose, milk (lactic acid, urea), and wine (acetic acid, total acidity, glucose, fructose, L-lactic acid, L-malic acid, and sucrose) [56] |
| **Pesticide residues:**                   | Organophosphates, thiophosphates, and carbamates [56]                      |
| **Seafood analysis:**                     | Amnesic shellfish poisoning (ASP), marine biotoxins (okadaic acid), histamine, and sulphite residues [56] |
| **Species identification:**               | Pork, horse, beef, fish, goat, poultry, rabbit and sheep [56]               |
| **Environmental monitoring devices**      | Water testing: Algae, alkalinity, aluminium, ammonia, arsenic, bleach, boron, bromine, cadmium, calcium hardness, carbon dioxide, chelant, chloride, chlorine, chromate, chromium, conductivity, copper, cyanuric acid, cyanide, detergents, dissolved oxygen, faecal streptococci, *E.Coli* and faecal coliforms, filming amine, fluoride, formaldehyde, glutaraldehyde, hardness, hydrazine, hydrogen peroxide, iodine, iron, lead, magnesium, manganese, molybdate/molybdenum, morpholine, nickel, nitrate, nitrite, oil in water, organophosphate, dissolved oxygen, ozone, quaternary ammonium compounds, peracetic acid, pH, phosphate, phosphonate, polyphosphates, polyquat, potassium, *Pseudomonas aeruginosa*, salinity, silica, sulphate, sulphide, sulphite, turbidity, total dissolved solids, tannin/lignin, tolcide PS biocide, and zinc [59–64] |
| **Soil:**                                 | Humus, organic matter, pH, and plant tissue macronutrient (texture) [60]    |
Typical approaches include the removal of contaminants from the samples to improve selectivity and sensitivity, and decrease the turnaround time. Additionally, the sample might require further processing to improve the signal-to-noise ratio. Sample preparation suffers from inhomogeneity, interfering agents, inhibitors, and it requires increasing the viscosity of samples such as whole blood and food samples. Increasing the sensitivity requires tedious sample preparation steps for low concentrations of target molecules or cells. The ideal sample preparation step should be cost-effective and is potentially executed in a single step. The desired outcome of the sample preparation is concentrating the target analyte(s) and reducing the background noise due to matrix interferences. Lateral-flow tests are low-cost, lightweight, portable, but the growing demand for higher sensitivity is challenging its current format [68]. For

### Table 1.1 (continued)

| Test | Application |
|------|-------------|
| Biothreat detection | Anthrax, plague, tularemia, ricin, botulinum toxin, *Staphylococcal enterotoxin B*, orthopox, *Brucella*, abrin, biological warfare simulants, nerve (G&V series), Category A-C biothreat agents, and blister (HD) agents, acids, bases, aldehydes and oxidisers [65–67] |

a Require minimal sample preparation  
b Urine collection and detection are often integrated in one cup

**Fig. 1.1** Lateral-flow point-of-care assays in the market and their cassette formats. a **Determine™** TB LAM Ag test.© (Alere), b **Directigen™** EZ Flu A + B (Beckton Dickinson), c **ImmunoCard STAT!™** E. coli O157 Plus (Meridian Bioscience), d A multiplex lateral-flow assay. RAID™ 5 for biological threat detection (Alexeter Technologies), e Schematic of the lateral-flow assay, and f flow-through assay. Adapted from Ref. [69] with permission from The Royal Society of Chemistry.
example, cardiac markers, biothreat and single cell detection require sensitivities that are not achievable with the existing assays. For these applications, lateral-flow tests must evolve and incorporate novel materials and labelling approaches. Progress in detection/quantification technologies, readout devices and manufacturing techniques will increase the reproducibility and sensitivity of lateral-flow assays. However, all these new advances must maintain the ultimate attractiveness of rapid tests: Sample-to-answer in a single step.

1.2 Sensing Mechanisms

A wide array of sensing mechanisms has been proposed for point-of-care diagnostic devices. Applications for such sensors include medical diagnostics, veterinary testing, environmental monitoring and food pathogen testing (Table 1.2). Sensing mechanisms demonstrated, with the exception of molecular dyes, required handheld readers. Excluding other types of sensors can be attributed to high costs, powering requirements and incompatibility with point-of-care assays.

1.2.1 Colorimetric Reagents

Molecular and enzymatic dyes are the simplest and most commonly used detection methods, which are semi-quantitatively interpreted by a colour reference chart. Urinalysis test strips such as Multistix (Siemens) and Chemstrip (Roche) are based on colorimetric reagents (Table 1.3). In advanced assays such as paper-based microfluidic devices, multiple detection zones are employed to capture different analytes within the same assay. Such multiplexed assays can be fabricated by printing wax channel-shaped patterns on paper/nitrocellulose, followed by heat treatment to form hydrophobic barriers in the matrix. The patterned regions can be spotted with enzymes, acid-base indicators or dyes in confined zones. Usually, a single inlet wicks the sample, which is distributed to the confined regions to react with the immobilised reagents. pH-, glucose- and protein-sensitive reagents have been used in paper-based microfluidic devices [70, 73]. In the glucose assay, a positive result is observed when the colour shifts from clear to brown due to the enzymatic oxidation of iodide to iodine. Similarly, a positive result in protein assays is interpreted from a colour change of tetrabromophenol blue from yellow to blue [70, 73]. Up to date, multiplex colorimetric assays included medical diagnostics [81, 87, 90, 91], environmental tests [76, 83, 84, 86, 89], and food quality tests [77, 88] (Fig. 1.2a). A disadvantage of colorimetric sensors is the inhomogeneity of the colour distribution and the coffee ring effect in the detection zones, and thus, the judgment of the final colour is challenging by eye [73]. In addition, colorimetric sensors are interfered by the background colour of the paper or the sample. For example, blood assays require
### Table 1.2 Rapid diagnostics: sensing mechanisms, their dynamic ranges and sensitivity/detection limits

| Analyte                                      | Dynamic range | Sensitivity/ detection Limit | Reference       |
|----------------------------------------------|---------------|------------------------------|-----------------|
| Bovine serum albumin                        | 0.38–75 µM    | 0.75 µM                      | [70, 71]        |
| Glucose                                      | 2.5–500 mM    | 5 mM                         | [70, 72–75]     |
| pH                                           | 5–9 pH units  | 0.5 pH units                 | [73]            |
| Human serum albumin                         | 0.46–46 µM    | 0.8 µM                       | [73]            |
| Bendiocarb                                   | <2 µM         | ~1 nm                        | [76]            |
| Carbaryl                                     | <2 µM         | ~10 nm                       | [76]            |
| Paraoxon                                     | <10 µM        | ~1 nm                        | [76]            |
| Malathion                                    | <10 µM        | ~10 nm                       | [76]            |
| Aflatoxin B1                                 | <40 µM        | ~30 nm                       | [77]            |
| Antibodies to the HIV-1 envelope antigen gp41 | 1:1–1:100 dilution of HIV in serum | 54 fmol/zone (rabbit IgG) | [78]            |
| Lactate                                      | 1–25 mM       | 1 mM                         | [74]            |
| Uric acid                                    | 0.1–7 mM      | 0.1 mM                       | [74, 75]        |
| Red cell antigens A, B, and D               | Qualitative   | N/A                          | [79, 80]        |
| Urinary acetoacetate                         | 5–16 mM       | 0.5 mM                       | [81]            |
| Salivary nitrite                             | 5 µM–2 mM     | 5 µM                         | [81]            |
| Total iron                                   | 50 µM–1 mM    | 44 µM                        | [82]            |
| Hg(II), Ag(I), Cu(II), Cd(II), Pb(II), Cr(VI), Ni(II) | 5.4–120.0 ppm | 0.001; 0.002; 0.020; 0.140; 0.150; 0.230 ppm | [83]            |
| Organic solvents                             | 5–100 % (v/v) | 5 % (v/v)                    | [84]            |
| Hydrogen peroxide                            | 0.1–10 ppm    | 0.4 ppm                      | [85]            |
| Volatile organic compounds                   | Qualitative   | Qualitative                  | [86]            |
| *E. coli* strain K12 ER2738                  | ~10^5–~10^9 colony forming unit | ~10^7 CFU | [87]            |
| *E. coli* O157:H7, *Salmonella Typhimurium*, and *L. monocytogenes* | 10–10^3 cfu/cm^2 | 10 cfu/cm^2 | [88]            |
| Particulate metal (Fe)                       | 1.5–15 µg     | 1.5 µg                       | [89]            |
| Particulate metal (Ni)                       | 1–15 µg       | 1 µg                         | [89]            |
| Particulate metal (Cu)                       | 1–15 µg       | 1 µg                         | [89]            |
| Alkaline phosphatase                         | <500 U/L      | ~15 U/L                      | [90]            |
| Aspartate aminotransferase                   | <300 U/L      | ~44 U/L                      | [90]            |
| Aspartate aminotransferase                   | 50–200 U/L    | ~84 U/L                      | [91]            |
| Alanine aminotransferase                     | 50–200 U/L    | ~53 U/L                      | [91]            |
| Airborne particulate matter                  | 10–100 pmol min^{-1} µg^{-1} | 0.32–0.65 ng | [92]            |
| Reactive phosphate                           | 0.2–10 mg L^{-1} | 0.05 mg L^{-1} | [93]            |

(continued)
| Analyte                          | Dynamic range    | Sensitivity/detection Limit | Reference                  |
|---------------------------------|------------------|-----------------------------|----------------------------|
| **Electrochemical sensing**     |                  |                             |                            |
| Glucose                         | <100 mM          | 0.21 mM                     | [94–97]                    |
| Lactate                         | <50 mM           | 0.36 mM                     | [94, 95]                   |
| Uric acid                       | <35 mM           | 1.38 mM                     | [94, 98]                   |
| Ascorbic acid                   | 0.05–0.4 mM      | 0.02 mmol L⁻¹               | [98]                       |
| Cholesterol                     | 20–200 mg/dL⁻¹   | 13 mg/dL⁻¹                  | [95]                       |
| Ethanol                         | 0.1–3 mM         | 0.2 mM                      | [95]                       |
| Pb(II)                          | <100 ppb         | 1.0 ppb                     | [96, 99, 100]              |
| Cd(II)                          | 10–100 ppb       | 2.3 ppb                     | [100]                      |
| Cancer and tumour markers       | <100 ng/mL or U/mL | 10⁻⁴ ng mL⁻¹, 3.7 × 10⁻⁵ and 2.6 × 10⁻⁵ U mL⁻¹, 2.0 × 10⁻⁵ ng mL⁻¹ | [101–104] |
| pH                              | 4–10             | 0.01 pH units               | [105]                      |
| K⁺ ions                         | 10⁻⁵–10⁻¹ M      | 4.1 × 10⁻⁶ M               | [105]                      |
| NH₄⁺ ions                       | 10⁻⁵–10⁻¹ M      | 7.2 × 10⁻⁶ M               | [105]                      |
| Dopamine                        | <100 µM          | 56.6 ± 1.1 mV/unit of pH    | [106]                      |
| Paracetamol                     | 0.05–2.00 mmol L⁻¹ | 25 µmol L⁻¹                | [107]                      |
| 4-aminophenol                   | 0.05–2.00 mmol L⁻¹ | 10 µmol L⁻¹               | [107]                      |
| 1-butanolthiol                  | 2–200 µM         | 0.5 µM                      | [108]                      |
| **Nanoparticles**               |                  |                             |                            |
| DNase I                         | 10⁻⁵–10⁻¹ unit/µL | 10⁻⁵ unit/µL               | [109]                      |
| Adenosine                       | <250 µM          | 11.8 µM                     | [110]                      |
| Human IgG                       | <5 mg/L          | 10 µg/L                     | [111]                      |
| Pseudomonas aeruginosa, Staphylococcus aureus | 0.5–10 × 10³ CFU/mL | 500–5,000 CFU/ml | [112]                      |
| Glucose                         | 0.5–100 mM       | 0.5 mM                      | [113]                      |
| Hg(II)                          | 5–75 ppm         | 0.12 ppm                    | [114]                      |
| PthHRP2                         | 5–40 ng/mL       | 2.9 ng/mL                   | [115]                      |
| Goat IgG                        | 0.05–1 µg/mL     | 20 ng mL⁻¹                 | [116]                      |
| Prostate-specific antigen       | 0.05–100 µg/L    | ~ 360.2 ng/L               | [117]                      |
| Cu²⁺ ions                       | 7.8–62.8 µM      | 7.8 nM                      | [118]                      |
| HIV DNA                         | 10–10⁶ HIV gag DNA | 10 copies                   | [119]                      |
| Mycobacterium tuberculosis      | < 30 µg mL⁻¹     | 10 µg mL⁻¹                 | [120]                      |
| Immunoglobulin E                | 0.05–5 pmol      | 50 fmol                     | [121]                      |
| Cd²⁺ ions                       | 10 ppb           | 0.1–0.4 ppb                 | [122]                      |

(continued)
### Table 1.2 (continued)

| Analyte                                      | Dynamic range          | Sensitivity/detection Limit | Reference |
|-----------------------------------------------|------------------------|----------------------------|-----------|
| **Electrochemiluminescence**                  |                        |                            |           |
| 2-(dibutylamino)-ethanol                      | 3 µM–10 mM             | 0.9 µM                     | [123]     |
| Nicotinamide adenine dinucleotide            | 0.2–20.0 mM            | 72 µM                      | [123]     |
| Tumour markers (AFP, CA125, CA199, CEA)      | 5–100 ng or U mL⁻¹     | 0.15 ng mL⁻¹, 0.6 and 0.17 U mL⁻¹, 0.5 ng mL⁻¹ | [103, 124, 125] |
| Carcinoembryonic antigens                    | 0.01–10 ng mL⁻¹        | 1 fg mL⁻¹                  | [126]     |
| Dopamine                                     | 1 µM–10 mM             | 1 µM                       | [127]     |
| Pb²⁺ ions                                    | <2 µM                  | 10 pM                      | [128]     |
| Hg²⁺ ions                                    | <2 µM                  | 0.2 nM                     | [128]     |
| Enzo[a]-pyrene (B[a]P)                       | 0.15–12.5 µM           | ~150 nM                    | [129]     |
| **Chemiluminescence**                        |                        |                            |           |
| Glucose                                      | 2.5–50 mM L⁻¹          | 0.14 mmol L⁻¹              | [130]     |
| Uric acid                                    | 2.5–50 mM L⁻¹          | 0.52 mmol L⁻¹              | [130, 131]|
| Tumour markers (AFP, CA153, CA199, CEA)      | <150 mM ng or U mL⁻¹   | 1.0 ng mL⁻¹, 0.4, and 0.06 U mL⁻¹ and 0.02 ng mL⁻¹ | [102, 132]|
| **Fluorescence**                             |                        |                            |           |
| Fluorescein isothiocyanate-labeled bovine serum albumin | 0.1–100 pmol       | 125 fmol                   | [133]     |
| DNA                                          | 10–10,000 pM           | 100 pM                     | [134]     |
| Nucleic acids                                | 0.08–5.00 µM           | 1,200 input templates      | [135]     |
| Lung cancer associated miRNA                 | 10 nM–10 µM            | ~100 nM                    | [136]     |
| Nucleic acid hybridisation                   | 1–5 pmol               | 300 fmol                   | [137]     |
| Asian soybean rust                           | 0.0032–3.2 mg/mL       | 2.2 mg/mL                  | [138]     |
| **Dual electrochemical/colorimetric sensing**|                        |                            |           |
| Au(III)                                      | 1–200 ppm              | 1 ppm                      | [139]     |
| **Bacterial whole-cell**                     |                        |                            |           |
| Bacterial quorum signalling molecules–N-acylhomoserine lactones | 10⁻⁹–10⁻⁴ M       | 10⁸ M                      | [140]     |
Table 1.3 The principles of colorimetric reactions in commercial urinalysis tests

| Assay  | Reaction                                                                 | Range     | Detection limit [144] |
|--------|--------------------------------------------------------------------------|-----------|-----------------------|
| Glucose| Glucose + O₂ $\xrightarrow{\text{glucose oxidase}}$ Gluconolactone + H₂O₂ | 5.5–55    | 2.2 mmol/L            |
|        | Chromogen + H₂O₂ $\xrightarrow{\text{peroxidase}}$ H₂O + dye             |           |                       |
| Protein| Tetrabromophenol blue (pH 3, yellow) $\xrightarrow{\text{protein}}$ tetrabromophenol blue (>pH 4.6, blue) | 30–300    | 6 mg/dL albumin       |
| Blood  | H₂O₂ + chromogen $\xrightarrow{\text{peroxidase}}$ oxidised chromogen + H₂O₂ | 10–80     | 5–10 erythrocytes/L   |
| Leukocytes| Indoxyl or pyrole carbonic acid ester $\xrightarrow{\text{esterase}}$ Indoxyl or pyrole | 15–125    | 10–25 leukocytes/µL   |
| Nitrite| Nitrite + p-arsanilic acid → diazonium compound                           | Qualitative| 11 µmol/L             |
| pH     | HInd (acid form) + H₂O $\rightleftharpoons$ H₃O⁺ + Ind⁻ (conjugate base of the indicator) | 4–9       | 0.25 pH units         |
| Ketone | Acetoacetic acid + Na nitroprusside + glycine $\xrightarrow{\text{alkaline}}$ violet to purple colour | 0.5–4.0   | 5 mg/dL               |
| Urobilinogen| p-diethylaminobenzaldehyde + urobilinogen $\rightarrow$ azo compound (red) | 17–200 µmol/L | 7 mol/L               |
| Bilirubin| Bilirubin + diazo $\xrightarrow{\text{acid}}$ azobilirubin                | ++++      | 9 µmol/L              |
either usage of serum/plasma samples or a red blood cell filter. Despite its drawbacks, colorimetric sensing is widely used, and it can also be quantified by a handheld reader [141, 142] or a smartphone camera [72, 143].

### 1.2.2 Electrochemical Sensors

Electrochemistry and ion-selective electrodes have been explored widely due to their well-known principle of operation and maturity. Traditionally, electrochemical sensors have three electrodes: a counter electrode, a working electrode, and a reference electrode. In paper-based assays, carbon ink was used for the counter and the working electrode, whereas silver/silver chloride ink was used for the fabrication of the reference electrode. The reaction zones comprised this multiple-electrode mechanism (Fig. 1.2b). Electrochemical sensors allowed the detection of glucose [94, 95], lactate [94, 95], uric acid [94], cholesterol [95], tumour markers [101], dopamine [106] and drugs [107]. Other studies described heavy metal sensors for environmental monitoring [94, 96, 99, 100]. As compared to colorimetric reagents, the fabrication of electrochemical sensors required an additional deposition step of conductive inks on the paper matrix. All these electrodes and electronic wires were screen printed using graphite and silver inks, respectively. When the sample was introduced to the device, it was wicked up into the sensing zones and the amperometric measurement was initiated via a glucometer. Alternatively, gold can be sputtered on the paper matrix through a shadow mask for the deposition of electrodes [107]. Such electrodes can be characterised by cyclic and square wave voltammetry, and chronoamperometry. In contrast to colorimetric reagents, electrochemical sensors respond within seconds and have sensitivities down to nM [145]. Electrochemical detection is also independent of the ambient light and is less prone to interference from the colour/deteriorations of substrate. Although the attributes of electrochemical detection such as maturity and suitability for miniaturisation are attractive, the requirement for a readout device increases its complexity and the cost per test.

![Fig. 1.2 Sensors utilised for point-of-care testing, a Colorimetric detection of heavy metals, b Electrochemical sensing of glucose, lactate and uric acid, c Antibody conjugated gold NP detection of Pseudomonas aeruginosa and Staphylococcus aureus, d ECL emission from a paper-based device at different analyte concentrations, e Fluorescent sensing for measuring bacterial growth. Adapted from Ref. [69] with permission from The Royal Society of Chemistry](image-url)
1.2 Sensing Mechanisms

1.2.3 Colloidal Nanoparticles (NPs)

Functionalised colloidal gold and monodisperse latex are the historical sensing reagents for lateral-flow assays, which do not require a readout device for qualitative results [146]. Lateral-flow tests employ antibody-conjugated gold NPs, which have extinction coefficients that are higher than common organic dyes. Inkjet printers have been used to deposit the NPs for multiplex detection on filter paper [111]. Other NP-based assay studies focused on improving the sensitivity of current lateral-flow tests by using paper network platforms. The 2D nitrocellulose-based networks enabled multistep processes to amplify the signal in immunoassays to improve the limit of detection [115, 147]. These cards contained reagents stored dry and the assay was activated by wicking the sample in a single-user step. They were capable of multistep processes such as delivering rinse buffers and signal amplification reagents to the capture zones. These devices were demonstrated by using porous materials such as nitrocellulose and cellulose depending on the sensing application. Other 2D paper networks involved integrating the inlets of a number of lateral flow assays [112] (Fig. 1.2c), adopting folding techniques [119] and microplate paper platforms [120]. NP-based detection has been demonstrated with metabolites [109, 111, 113, 117, 121, 147], bacterial agents [112] in disease diagnosis such as HIV [119], malaria [115], tuberculosis [120] and in environmental monitoring [114, 118]. To multiplex the assay, monodisperse latex can be coupled with fluorescent and coloured dyes, and para/magnetic components. For example, conjugated with dark dyes, monodisperse latex particles exhibit high contrast on nitrocellulose or paper. Additionally, latex particles can be utilised with different colours or fluorescent dyes.

1.2.4 Chemiluminescence (CL)

CL is based on the emission of light generated by a chemical reaction. In the presence of reactants A (luminol) and B (H₂O₂), and a catalyst or excited intermediate (3-aminophthalate), light is produced along with side products. Peroxidase catalyses the oxidation of luminol to 3-aminophthalate, and the decay of the excited state (◊) to a lower energy level results in light emission, which can be enhanced by using phenol derivatives such as p-iodophenol. A typical example of CL is the glow stick, which is based on the reaction of peroxide with a phenyl oxalate ester ([A] + [B] → [◊] → [products] + light). In rapid diagnostics, CL has been explored for the detection of glucose and uric acid [130] and tumour markers [132, 148]. Glucose and uric acid assays were based on oxidase reactions coupled with chemiluminescence reactions of a rhodanine derivative with the generated H₂O₂ in an acidic medium [130]. Uric acid was determined through a chemiluminescence reaction between the rhodanine derivative (3-p-nitrylphenyl-5-(40-methyl-20-sulphonophenylazo) rhodanine) and
H$_2$O$_2$ [131]. Studies on the detection of tumour markers involved fabricating sandwich-type immunoassays with a typical luminol-H$_2$O$_2$ chemiluminescence system catalysed by Ag$^0$ NPs [132]. Detection of tumour markers was also achieved by sandwich CL-ELISA with antibodies that were covalently immobilised on a chitosan modified paper zone through glutaraldehyde cross-linking [148]. Correlating the concentration of the analyte and the peak intensity of the emitted light allowed quantitative analysis.

1.2.5 Electrochemiluminescence (ECL)

This sensing mechanism is based on luminescence generated by electrochemical reactions. When electrochemically generated intermediates undergo exergonic reactions, they result in an electronically excited state. This state emits light upon relaxation to a lower level state, and therefore it enables readouts without the requirement for a photodetector. ECL has the advantages of both luminescence and electrochemistry. An ECL sensor based on orange luminescence was demonstrated through the detection of 2-(dibutylamino)-ethanol (DBAE) and nicotinamide adenine dinucleotide by readouts of luminescence [123]. The principle of ECL sensor was based on Ru (bpy)$_2$($\text{DBAE}$)$^+$ and DBAE. At the electrode, the amine was oxidised and formed a radical cation [DBAE•]$^+$, followed by deprotonation to create a DBAE• radical, which reduced Ru (bpy)$_3$($\text{DBAE}$)$^+$ to an excited state. Eventually, Ru (bpy)$_3$($\text{DBAE}$)$^+$ emitted light at 620 nm while relaxing to the ground state [149]. This mechanism served as a coreactant that was oxidised solely by the electrode. In ECL, the electrochemical potential initiated and controlled the chemiluminescence reaction. The electrodes were printed using screen printing and adding an ECL active luminophore followed by drying. The substrates were laminated onto a Zensor screen-printed electrode using an office laminator. The cyclic voltammetry of Ru (bpy)$_3$ was used to characterise the electrodes. After the lamination step, an incision was made in the laminate layer. After the introduction of the sample to the assay, the potential was stepped from 0 to 1.15 V for a short period to initiate the ECL. The initiation can be achieved by shifting the potential to a level more positive than the oxidation potential of the ruthenium complex. Chronoamperometry was adopted to generate ECL since it provided control over the reaction time (Fig. 1.2d). The ECL readouts were taken with a camera phone housing to block the ambient light. ECL was connected to the mobile phone battery to obtain a short pulse of low voltage. In addition to these drawbacks, ECL required a photomultiplier tube, which was costly in a miniaturised form. The data was analysed based on the red pixel intensity of the ECL emission, which was correlated with a calibration curve, hence the analyte concentration. Other applications to date included sensing tumour markers [103, 124, 126] and ions [128].
1.2.6 Fluorescence

This detection mechanism was first demonstrated on paper microzone plates. Although paper-based plates are known [150–153], they have recently been suggested for quantitative fluorescence measurements. These paper plates require low sample volumes; 12.5 pmol of fluorescein isothiocyanate-labeled bovine serum albumin generated a relative fluorescence of 2,700 ± 850 a.u. [133]. Although concentration sensitivity and mass sensitivity were comparable with plastic plates, the average relative standard deviation for the replicates of all concentrations was higher. This limitation was attributed to light scattering on the cellulose fibres and the influence of the index of refraction between cellulose and air. Although paper-based plates were suggested as alternatives to conventional plastic multiwell plates, their interpretation required a microplate reader. Other notable studies adopting fluorescent sensing included paper strips comprising DNA-conjugated microgels (MG) for DNA detection [134]. Sensing DNA was accomplished by: (i) targeting DNA promoted ligation of a DNA primer to the MG-bound DNA, (ii) rolling circle amplification (RCA) between the primer and a circle DNA, and (iii) hybridisation of the RCA products and a fluorescent DNA probe. Another study reported a portable device for the growth of bacteria or the amplification of bacteriophages. A fluorescent mCherry reporter was used to quantify the growth of bacteria and the concentration of arabinose [87] (Fig. 1.2e). Another paper-based platform involving fluorescent sensing described the use of non-enzymatic nucleic acid circuits based on strand exchange reactions for the detection of target sequences [135]. Overall, although fluorescence sensing brings new capabilities to point-of-care diagnostics, the feasibility requires reduction in cost and miniaturisation of fluorescence readers.

1.2.7 Genetically-Engineered Cells

Bacterial quorum signalling (QS) molecules, N-acyl homoserine lactones (AHLs), have been used as a sensing mechanism [140]. The bacterial cell-based sensing system comprised two main components: (i) AHL-mediated QS regulatory system as recognition elements, and (ii) β-galactosidase as the reporter enzyme. The bacterial cells were inoculated on paper by liquid drying. The paper strip biosensor detected low concentrations (0.1 nM) of AHLs in saliva. The advent of synthetic biology will accelerate the development of whole-cell based biosensors.

1.3 Next Generation Diagnostics

To expand the current capabilities of point-of-care diagnostics, the materials, sensors and readout devices need to evolve. Extending beyond strip tests and lateral-flow design to multiplexed miniaturised assay configurations will put the
existing diagnostics in a context that will allow differentiation of conditions with similar symptoms and improve the treatment options. Biofunctional materials and synthesis of reversibly responsive compounds could lead to reusable tests, which might be applicable to conditions where frequent measurements are required. The control over structural design parameters, advances in deposition of materials through printing will play greater roles in the realisation of the new generation diagnostics. Studies on substate-protein/enzyme interactions, surface energy, release characteristics, assay decay will gain momentum in the realisation of diagnostics beyond R&D. Optimisation of capillary flow parameters in lateral-flow devices and advanced microfluidic devices will allow construction of assays with improved control and sensitivity. To date, limited studies in microfluidic platforms have employed unprocessed samples. Incorporation of sample preparation should not be overlooked. Furthermore, the performance of assay after long-term storage, and time-consuming sensor response in colorimetric test require further investigations. Sensing and detection technologies will also evolve. The search for sensing, quantification and readout within a single equipment-free assay will play a greater role in future diagnostics. These attributes may include user-friendly, fool-proof, text/quantity-reporting capabilities and unexplored sensing mechanisms such as paramagnetic particles, quantum dots, coloured latex particles, and genetically engineered whole cells based on synthetic biology, and other novel materials including graphene, plasmonic materials, and printable gratings [154–159]. In improving the sensitivity and providing a user-friendly interface, bioinspired photonic structures, colloidal crystal arrays, diffraction gratings and holographic sensors can offer newer capabilities and readout approaches [160–165]. Some of these sensing and readout mechanisms might not require physically blocking or shaping the substrate for multiplexing. Although significant time has been devoted to quantification with smartphones/handheld readers, equipment-free approaches should not be overlooked. The use of external readers is a barrier for existing assays, yet this requirement will be a greater challenge in adopting newer sensing platforms. The fast-growing mobile phone market in the developing world has made camera phones a potential platform for quantitatively reading diagnostic assays, and this may standardise the readout devices with improved connectivity [166, 167]. Novel approaches towards instrument-free quantification of analytes will be important contributions to the field. Additionally, the trends show that the microfluidic assay formats will be exploited further by the in vitro diagnostics industry [168–170]. All these advances will lead to multiplexed diagnostics that are capable of identifying the specific etiological agent that causes a particular syndrome, which is a goal that has not been achieved yet. Such assays can explore less utilised clinical samples such as tear fluid with contact lens sensors [171].

Existing prototypes need to be transformed into highly reproducible diagnostic devices. Having performance data does not always yield efficacy after deployment. Possible small-scale trials should experiment with the feasibility and cost-effectiveness after scaling up. The ultimate test in the realisation of diagnostics depends on the acceptance from experts in the commercial diagnostics industry. Today, the rapid diagnostics business is based on a standard lateral flow format, involving the
use of nitrocellulose as the reaction matrix. The lateral-flow format is the only ubiquitous, universally applicable platform that can be utilised for simple, qualitative, low cost point-of-care applications, while also having enough capability to be functionalised for highly sensitive, fully quantified, multiplexed assays. Hence, the industrial partners are seeking technologies that have improved capabilities, sensitivity, specificity, and compatibility with the existing manufacturing processes. Only low cost is not enough to achieve market penetration in diagnostics. The value of the low-cost and multiplexed diagnostics will be realised upon reaching communities, where they are needed the most.

References

1. Hagist C, Kotlikoff LJ (2009) Who’s going broke? Comparing growth in public healthcare expenditure in ten OECD countries. Hacienda Publica Esp 188:55–72
2. Which path will you take? (2007). Pharma 2020: The vision. PricewaterhouseCoopers
3. Medicines and older people implementing medicines-related aspects of the NSF for older people (2001) Department of Health, United Kingdom, 23634
4. Whitesides GM (2009) A lab the size of a postage stamp, TEDX Boston. http://www.ted.com. Accessed 27 Oct 2014
5. Akram MS, Daly R, Vasconcellos FC, Yetisen AK, Hutchings I, Hall EAH (2015) Applications of paper-based diagnostics. In: Castillo-Leon J, Svendsen WE (eds) Lab-on-a-chip devices and micro-total analysis systems. Springer
6. Nkengasong JN, Mesele T, Orloff S, Kebede Y, Fonjungo PN, Timperi R, Birx D (2009) Critical role of developing national strategic plans as a guide to strengthen laboratory health systems in resource-poor settings. Am J Clin Pathol 131(6):852–857. doi:10.1309/AJCPC51BLOBBPAKC
7. Schull MJ, Banda H, Kathyola D, Fairall L, Martiniuk A, Bursiul B, Zwarenstein M, Sodhi S, Thompson S, Joshua M, Mondiwa M, Bateman E (2010) Strengthening health human resources and improving clinical outcomes through an integrated guideline and educational outreach in resource-poor settings: a cluster-randomized trial. Trials 11:118. doi:10.1186/1745-6215-11-118
8. Lee HH, Allain JP (2004) Improving blood safety in resource-poor settings. Vox Sang 87 (Suppl 2):176–179. doi:10.1111/j.1741-6892.2004.00479.x
9. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, Pittet D (2011) Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 377(9761):228–241. doi:10.1016/S0140-6736(10)61458-4
10. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, Wilson P, Dahl CA, Buchsbaum S, Moeller G, Burgess DCH (2006) Requirements for high impact diagnostics in the developing world. Nature 444(Suppl 1):73–79. doi:10.1038/nature05448
11. Newton PN, Green MD, Fernandez FM, Day NPJ, White NJ (2006) Counterfeit anti-infective drugs. Lancet Infect Dis 6(9):602–613. doi:10.1016/S1473-3099(06)70581-3
12. Yager P, Domingo GJ, Gerdes J (2008) Point-of-care diagnostics for global health. Annu Rev Biomed Eng 10:107–144. doi:10.1146/annurev.bioeng.10.061807.160524
13. Mao X, Huang TJ (2012) Microfluidic diagnostics for the developing world. Lab Chip 12 (8):1412–1416. doi:10.1039/c2lc90022j
14. Water quality for ecosystem and human health (2008) 2 edn. GEMS/Water programme office, UN, Burlington, Ontario, Canada
15. Animal health and the millenium development goals (2010) Animal production and health division, Food and Agriculture Organization of the United Nations
16. Aluwong T, Bello M (2010) Emerging diseases and implications for Millennium Development Goals in Africa by 2015—an overview. Vet Ital 46(2):137–145
17. Global strategy for food safety: safer food for better health (2002) (trans: Department FS). Food Safety Department, WHO, Geneva, Switzerland
18. Bhandari N, Mazumder S, Taneja S, Sommerfelt H, Strand TA, Group IES (2012) Effect of implementation of Integrated Management of Neonatal and Childhood Illness (IMNCI) programme on neonatal and infant mortality: cluster randomised controlled trial. BMJ 344: e1634. doi:10.1136/bmj.e1634
19. Mazumder S, Taneja S, Bahl R, Mohan P, Strand TA, Sommerfelt H, Kirkwood BR, Goyal N, Van Den Hombergh H, Martines J, Bhandari N, Integrated Management of N, Childhood Illness Evaluation Study G (2014) Effect of implementation of Integrated Management of Neonatal and Childhood Illness programme on treatment seeking practices for morbidities in infants: cluster randomised trial. BMJ 349:g4988. doi:10.1136/bmj.g4988
20. Butler D (2010) Cholera tightens grip on Haiti. Nature 468(7323):483–484. doi:10.1038/468483a
21. Andrews JR, Basu S (2011) Transmission dynamics and control of cholera in Haiti: an epidemic model. Lancet 377(9773):1248–1255. doi:10.1016/S0140-6736(11)60273-0
22. Sack DA (2011) How many cholera deaths can be averted in Haiti? Lancet 377 (9773):1214–1216. doi:10.1016/S0140-6736(11)60356-5
23. Walton DA, Ivers LC (2011) Responding to cholera in post-earthquake Haiti. N Engl J Med 364(1):3–5. doi:10.1056/NEJMp1012997
24. Zarocostas J (2011) Cholera epidemic in Haiti is blamed on poor sanitation. BMJ 342:d2944. doi:10.1136/bmj.d2944
25. Webster PC (2011) Lack of clean water exacerbates cholera outbreak in Haiti. Can Med Assoc J (journal de l’Association medicale canadienne) 183(2):E83–E84. doi:10.1503/cmaj.109-3764
26. Free AH, Adams EC, Kercher ML, Free HM, Cook MH (1957) Simple specific test for urine glucose. Clin Chem 3(3):163–168
27. Singer JM, Plotz CM (1956) The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. Am J Med 21(6):888–892. doi:10.1016/0002-9343(56)90103-6
28. Berson SA, Yalow RS (1959) Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 38:1996–2016. doi:10.1172/JCI103979
29. Southern EM (1975) Detection of specific sequences among DNA fragments separated by Gel-Electrophoresis. J Mol Biol 98(3):503. doi:10.1016/S0022-2836(75)80083-0
30. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76(9):4350–4354
31. Goldberg DA (1980) Isolation and partial characterization of the drosophila alcohol dehydrogenase gene. Proc Natl Acad Sci USA 77(10):5794–5798
32. Hawkes R, Niday E, Gordon J (1982) A dot-immunobinding assay for monoclonal and other antibodies. Anal Biochem 119(1):142–147
33. Vaitukaitis JL, Braunstein GD, Ross GT (1972) A radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Am J Obstet Gynecol 113(6):751–758
34. Swiss Precision Diagnostics (2014) GmbH, Geneva, Switzerland. http://www.swissprecisiondiagnostics.com. Accessed 27 Oct 2014
35. Chemstrip® Test Strips. (2014) http://www.poc.roche.com. Accessed 27 Oct 2014
36. Multistix® 10 SG Reagent Strips. (2014) http://www.medical.siemens.com. Accessed 27 Oct 2014
37. Medi-test Combi 11 (2014) http://www.mn-net.com. Accessed 27 Oct 2014
38. Arkray AUTION (2014) Sticks. http://www.arkray.co.jp/english. Accessed 27 Oct 2014
39. YD diagnostics URiSCAN Strips (2014) http://www.yd-diagnostics.com. Accessed 27 Oct 2014
40. Chemstrip® Micral Test Strips (2014) http://www.poc.roche.com. Accessed 27 Oct 2014
41. CLINITEK® Microalbumin Reagent Strips (2014) http://www.medical.siemens.com. Accessed 27 Oct 2014
42. American Bio Medica Corporation (2014) (Kinderhook, New York). http://www.abmc.com. Accessed 27 Oct 2014
43. MP Biomedicals (2014) (Santa Ana, CA). http://www.mpbio.com. Accessed 27 Oct 2014
44. Craig Medical Distribution, Inc. (2014) (Vista, CA). http://www.craigmicalmedical.com. Accessed 27 Oct 2014
45. Alfa Scientific Designs, Inc. (2014) (Poway, CA). http://www.alfascientific.com. Accessed 27 Oct 2014
46. Alere Inc. (2014) (Waltham, MA). http://www.alere.com. Accessed 27 Oct 2014
47. Beckton Dickinson (2014) (Franklin Lakes, NJ). http://www.bd.com. Accessed 27 Oct 2014
48. QUIDEL Corporation (2014) (San Diego, CA). http://www.quidel.com. Accessed 27 Oct 2014
49. Beckman Coulter, Inc., Diagnostics Division (2014) (Brea, CA). http://www.beckmancoulter.com. Accessed 27 Oct 2014
50. Meridian Bioscience, Inc. (2014) (Cincinnati, OH). http://www.meridianbioscience.com. Accessed 27 Oct 2014
51. Audit Diagnostics (2014) (Carrigtwohill, Ireland). http://www.auditdiagnostics.ie. Accessed 27 Oct 2014
52. Abaxis Inc. (2014) (Union City, CA). http://www.abaxis.com/veterinary/. Accessed 27 Oct 2014
53. Biomedica MedizinProdukte (2014) GmbH & Co KG, Vienna, Austria. http://www.biomedica.co.at. Accessed 27 Oct 2014
54. Henry Schein, Inc. (2014) (Langen, Germany). http://www.henryscheinbrand.com. Accessed 27 Oct 2014
55. Romer Labs, Inc. (2014) (Union, MO). http://www.romerlabs.com. Accessed 27 Oct 2014
56. Neogen Corporation, (2014) (Lansing, MI). http://www.neogen.com. Accessed 27 Oct 2014
57. Charm Sciences, Inc. (2014) (Lawrence, MA). http://www.charm.com. Accessed 27 Oct 2014
58. Kwinbon Biotechnology Co., Ltd. (2014) (Beijing, China). http://www.kwinbon.com. Accessed 27 Oct 2014
59. Wagtech WTD, Palintest Ltd (2014) (Gateshead, U.K.). http://www.wagtech.co.uk. Accessed 27 Oct 2014
60. LaMotte Company (2014) (Chestertown, Maryland). http://www.lamotte.com. Accessed 27 Oct 2014
61. YSI Inc. (2014) (Yellow Springs, Ohio). http://wwwysi.com. Accessed 27 Oct 2014
62. Obresco-Hellige (2014) (Sarasota, FL). http://www.orbeco.com/. Accessed 27 Oct 2014
63. HANNA Instruments US Inc. (2014) (Woonsocket, RI). http://www.hannainst.com. Accessed 27 Oct 2014
64. Industrial Test Systems, Inc. (2014) (Rock Hill, SC). http://www.senssale.com. Accessed 27 Oct 2014
65. Southern Scientific Ltd (2014) (Henfield, U.K.). http://www.southernscientific.co.uk. Accessed 27 Oct 2014
66. Alexeter Technologies LLC (2014) (Chicago, IL). http://www.alexeter.com. Accessed 27 Oct 2014
67. Miprolab (2014) GmbH (Göttingen, Germany). http://www.miprolab.com. Accessed 27 Oct 2014
68. Wong RC, Tse HY (2009) Lateral flow immunoassay. Humana Press, Springer, New York. doi:10.1007/978-1-59745-240-3
69. Yetisen AK, Akram MS, Lowe CR (2013) Paper-based microfluidic point-of-care diagnostic devices. Lab Chip 13(12):2210–2251. doi:10.1039/c3lc50169h
70. Martinez AW, Phillips ST, Butte MJ, Whitesides GM (2007) Patterned paper as a platform for inexpensive, low-volume, portable bioassays. Angew Chem Int Ed 46(8):1318–1320. doi:10.1002/anie.200603817

71. Zhang AL, Zha Y (2012) Fabrication of paper-based microfluidic device using printed circuit technology. AIP Adv 2:022171. doi:10.1063/1.4733346

72. Martinez AW, Phillips ST, Carrilho E, Thomas SW 3rd, Sindi H, Whitesides GM (2008) Simple telemedicine for developing regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal Chem 80(10):3699–3707. doi:10.1021/ac800112r

73. Abe K, Suzuki K, Citterio D (2008) Inkjet-printed microfluidic multianalyte chemical sensing paper. Anal Chem 80(18):6928–6934. doi:10.1021/ac800604v

74. Dungchai W, Chailapakul O, Henry CS (2010) Use of multiple colorimetric indicators for paper-based microfluidic devices. Anal Chim Acta 674(2):227–233. doi:10.1016/j.aca.2010.06.019

75. Chen X, Chen J, Wang F, Xiang X, Luo M, Ji X, He Z (2012) Determination of glucose and uric acid with bienzyme colorimetry on microfluidic paper-based analysis devices. Biosens Bioelectron 35(1):363–368. doi:10.1016/j.bios.2012.03.018

76. Hossain SM, Luckham RE, McFadden MJ, Brennan JD (2009) Reagentless bidirectional lateral flow bioactive paper sensors for detection of pesticides in beverage and food samples. Anal Chem 81(21):9055–9064. doi:10.1021/ac901714h

77. Hossain SM, Luckham RE, Smith AM, Lebert JM, Davies LM, Pelton RH, Filipe CD, Brennan JD (2009) Development of a bioactive paper sensor for detection of neurotoxins using piezoelectric inkjet printing of sol-gel-derived bioinks. Anal Chem 81(13):5474–5483. doi:10.1021/ac900660p

78. Cheng CM, Martinez AW, Gong J, Mace CR, Phillips ST, Carrilho E, Mirica KA, Whitesides GM (2010) Paper-based ELISA. Angew Chem Int Ed Engl 49(28):4771–4774. doi:10.1002/anie.201001005

79. Khan MS, Thouas G, Shen W, Whyte G, Garnier G (2010) Paper diagnostic for instantaneous blood typing. Anal Chem 82(10):4158–4164. doi:10.1021/ac100341n

80. Al-Tamimi M, Shen W, Zeineddine R, Tran H, Garnier G (2012) Validation of paper-based assay for rapid blood typing. Anal Chem 84(3):1661–1668. doi:10.1021/ac202948t

81. Klasner SA, Price AK, Hoeman KW, Wilson RS, Bell KJ, Culbertson CT (2010) Paper-based microfluidic devices for analysis of clinically relevant analytes present in urine and saliva. Anal Bioanal Chem 397(5):1821–1829. doi:10.1007/s00216-010-3718-4

82. Dungchai W, Chailapakul O, Henry CS (2011) A low-cost, simple, and rapid fabrication method for paper-based microfluidics using wax screen-printing. Analyst 136(1):77–82. doi:10.1039/c0an00906e

83. Hossain SM, Brennan JD (2011) beta-galactosidase-based colorimetric paper sensor for determination of heavy metals. Anal Chem 83(22):8772–8778. doi:10.1021/ac102290d

84. Pumtang S, Siripornnoppakhun W, Sukwattanasinitt M, Ajavakom A (2011) Solvent colorimetric paper-based polydiacetylene sensors from diacetylene lipids. J Colloid Interf Sci 364(2):366–372. doi:10.1016/j.jcis.2011.08.074

85. Xu M, Bunes BR, Zang L (2011) Paper-based vapor detection of hydrogen peroxide: colorimetric sensing with tunable interface. ACS Appl Mater Interfaces 3(3):642–647. doi:10.1021/am1012535

86. Eaidkong T, Mungkarndee R, Phollookin C, Tumcharern G, Sukwattanasinitt M, Wacharasindhu S (2012) Polydiacetylene paper-based colorimetric sensor array for vapor phase detection and identification of volatile organic compounds. J Mater Chem 22(13):5970–5977. doi:10.1039/C2jm16273c

87. Funes-Huacca M, Wu A, Szepesvari E, Rajendran P, Kwan-Wong N, Razgulin A, Shen Y, Kagira J, Campbell R, Derda R (2012) Portable self-contained cultures for phage and bacteria made of paper and tape. Lab Chip 12(21):4269–4278. doi:10.1039/C2lc40391a
88. Jokerst JC, Adkins JA, Bisha B, Mentele MM, Goodridge LD, Henry CS (2012) Development of a paper-based analytical device for colorimetric detection of select foodborne pathogens. Anal Chem 84(6):2900–2907. doi:10.1021/ac203466y

89. Mentele MM, Cunningham J, Koehler K, Volckens J, Henry CS (2012) Microfluidic paper-based analytical device for particulate metals. Anal Chem 84(10):4474–4480. doi:10.1021/ac300309c

90. Vella SJ, Beattie P, Cademartiri R, Laromaine A, Martinez AW, Phillips ST, Mirica KA, Whitesides GM (2012) Measuring markers of liver function using a micropatterned paper device designed for blood from a fingerstick. Anal Chem 84(6):2883–2891. doi:10.1021/ac203434x

91. Pollock NR, Rolland JP, Kumar S, Beattie PD, Jain S, Noubary F, Wong VL, Pohlmann RA, Ryan US, Whitesides GM (2012) A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med 4(152):152ra129. doi:10.1126/scitranslmed.3003981

92. Sameenoi Y, Panymeesamer P, Supalakorn N, Koehler K, Chailapakul O, Henry CS, Volckens J (2013) Microfluidic paper-based analytical device for aerosol oxidative activity. Environ Sci Technol 47(2):932–940. doi:10.1021/es304662w

93. Jayawardane BM, McKelvie ID, Kolev SD (2012) A paper-based device for measurement of reactive phosphate in water. Talanta 100:454–460. doi:10.1016/j.talanta.2012.08.021

94. Dungchai W, Chailapakul O, Henry CS (2009) Electrochemical detection of Pb and Cd in paper-based microfluidics. Anal Chem 81(14):5821–5826. doi:10.1021/ac9007573

95. Nie Z, Deiss F, Liu X, Akbulut O, Whitesides GM (2010) Integration of paper-based microfluidic devices with commercial electrochemical readers. Lab Chip 10(22):3163–3169. doi:10.1039/c0lc00237b

96. Nie Z, Nijhuis CA, Gong J, Chen X, Kumachev A, Martinez AW, Narovlyansky M, Whitesides GM (2010) Electrochemical sensing in paper-based microfluidic devices. Lab Chip 10(4):477–483. doi:10.1039/b917150a

97. Liu H, Crooks RM (2012) Paper-based electrochemical sensing platform with integral battery and electrochromic read-out. Anal Chem 84(5):2528–2532. doi:10.1021/ac203457b

98. Carvalhal RF, Kfouri MS, Piazetta MH, Gobbi AL, Kubota LT (2010) Electrochemical detection in a paper-based separation device. Anal Chem 82(3):1162–1170. doi:10.1021/ac902647r

99. Tan SN, Ge L, Wang W (2010) Paper disk on screen printed electrode for one-step sensing with an internal standard. Anal Chem. doi:10.1021/ac1015062

100. Shi JJ, Tang F, Xing HL, ZhengHX, Bi LH, Wang W (2012) Electrochemical detection of Pb and Cd in paper-based microfluidic devices. J Brazil Chem Soc 23(6):1124–1130

101. Ge S, Ge L, Yan M, Song X, Yu J, Huang J (2012) A disposable paper-based electrochemical sensor with an addressable electrode array for cancer screening. Chem Commun 48(75):9397–9399. doi:10.1039/c2cc34887j

102. Wang P, Ge L, Yan M, Song X, Ge S, Yu J (2012) Paper-based three-dimensional electrochemical immunodevice based on multi-walled carbon nanotubes functionalized paper for sensitive point-of-care testing. Biosens Bioelectron 32(1):238–243. doi:10.1016/j.bios.2011.12.021

103. Wang S, Ge L, Zhang Y, Song X, Li N, Ge S, Yu J (2012) Battery-triggered microfluidic paper-based multiplex electrochemiluminescence immunodevice based on potential-resolution strategy. Lab Chip 12(21):4489–4498. doi:10.1039/c2lc40707h

104. Zhang D, Ge L, Yan M, Song X, Yu J (2012) Electrochemical immunoassay on a 3D microfluidic paper-based device. Chem Commun 48(39):4683–4685. doi:10.1039/c2cc16958d

105. Novell M, Parrilla M, Crespo GA, Rius FX, Andrade FJ (2012) Paper-based ion-selective potentiometric sensors. Anal Chem 84(11):4695–4702. doi:10.1021/ac202979j

106. Rattanarat P, Dungchai W, Siangproh W, Chailapakul O, Henry CS (2012) Sodium dodecyl sulfate-modified electrochemical paper-based analytical device for determination of dopamine levels in biological samples. Anal Chim Acta 744:1–7. doi:10.1016/j.aca.2012.07.003
107. Shiroma LY, Santhiago M, Gobbi AL, Kubota LT (2012) Separation and electrochemical detection of paracetamol and 4-aminophenol in a paper-based microfluidic device. Anal Chim Acta 725:44–50. doi:10.1016/j.aca.2012.03.011

108. Dossi N, Toniolo R, Pizzariello A, Carrilho E, Piccin E, Battiston S, Bontempselli G (2012) An electrochemical gas sensor based on paper supported room temperature ionic liquids. Lab Chip 12(1):153–158. doi:10.1039/c1lc20663j

109. Zhao WA, Ali MM, Aguirre SD, Brook MA, Li YF (2008) Paper-based bioassays using gold nanoparticle colorimetric probes. Anal Chem 80(22):8431–8437. doi:10.1021/Ac801008q

110. Liu H, Xiang Y, Lu Y, Crooks RM (2012) Aptamer-based origami paper analytical device for electrochemical detection of adenosine. Angew Chem Int Ed Engl 51(28):6925–6928. doi:10.1002/anie.201202929

111. Abe K, Koteru K, Suzuki K, Citterio D (2010) Inkjet-printed paperfluidic immuno-chemical sensing device. Anal Bioanal Chem 398(2):885–893. doi:10.1007/s00216-010-4011-2

112. Li CZ, Vandenberg K, Prabhulkar S, Zhu X, Schnepf L, Methée K, Rossler CJ, Almeide E (2011) Paper based point-of-care testing disc for multiplex whole cell bacteria analysis. Biosens Bioelectron 26(11):4342–4348. doi:10.1016/j.bios.2011.04.035

113. Ornatska M, Sharpe E, Andreescu D, Andreescu S (2011) Paper bioassay based on ceria nanoparticles as colorimetric probes. Anal Chem 83(11):4273–4280. doi:10.1021/ac200697y

114. Apilux A, Siangproh W, Praphairaksit N, Chailapakul O (2012) Simple and rapid colorimetric detection of Hg(II) by a paper-based device using silver nanoplates. Talanta 97:388–394. doi:10.1016/j.talanta.2012.04.050

115. Fu E, Liang T, Spicar-Mihalic P, Houghtaling J, Ramachandran S, Yager P (2012) Two-dimensional paper network format that enables simple multistep assays for use in low-resource settings in the context of malaria antigen detection. Anal Chem 84(10):4574–4579. doi:10.1021/ac300689s

116. Liang J, Wang YY, Liu B (2012) Paper-based fluorimmunoassay for rapid and sensitive detection of antigen. RSC Adv 2(9):3878–3884. doi:10.1039/C2ra20156a

117. Nie J, Zhang Y, Lin L, Zhou C, Li S, Zhang L, Li J (2012) Low-cost fabrication of paper-based microfluidic devices by one-step plotting. Anal Chem 84(15):6331–6335. doi:10.1021/ac203496c

118. Ratanaratthorn N, Chailapakul O, Henry CS, Dungchai W (2012) Simple silver nanoparticle colorimetric sensing for copper by paper-based devices. Talanta 99:552–557. doi:10.1016/j.talanta.2012.06.033

119. Rohrman BA, Richards-Kortum RR (2012) A paper and plastic device for performing recombinase polymerase amplification of HIV DNA. Lab Chip 12(17):3082–3088. doi:10.1039/c2lc40423k

120. Veigas B, Jacob JM, Costa MN, Santos DS, Viveiros M, Inacio J, Martins R, Barquinha P, Fortunato E, Baptista PV (2012) Gold on paper-paper platform for Au-nanoprobe TB detection. Lab Chip 12(22):4802–4808. doi:10.1039/c2lc04073f

121. Szucs J, Gyurcsanyi RE (2012) Towards protein assays on paper platforms with potentiometric detection. Electroanal 24(1):146–152. doi:10.1002/elan.201100522

122. Lopez Marzo AM, Pons J, Blake DA, Merkoci A (2013) All-integrated and highly sensitive paper based device with sample treatment platform for Cd(2+) immunodetection in drinking/tap waters. Anal Chem 85(7):3532–3538. doi:10.1021/ac3034536

123. Delaney JL, Hogan CF, Tian J, Shen W (2011) Electrogenerated chemiluminescence detection in paper-based microfluidic sensors. Anal Chem 83(4):1300–1306. doi:10.1021/ac102392t

124. Ge L, Yan J, Song X, Yan M, Ge S, Yu J (2012) Three-dimensional paper-based electrochemiluminescence immunodevice for multiplexed measurement of biomarkers and point-of-care testing. Biomaterials 33(4):1024–1031. doi:10.1016/j.biomaterials.2011.10.065

125. Li W, Li M, Ge S, Yan M, Huang J, Yu J (2013) Battery-triggered ultrasensitive electrochemiluminescence detection on microfluidic paper-based immunodevice based on dual-signal amplification strategy. Anal Chim Acta 767:66–74. doi:10.1016/j.aca.2012.12.053
126. Yan J, Ge L, Song X, Yan M, Ge S, Yu J (2012) Paper-based electrochemiluminescent 3D immunodevice for lab-on-paper, specific, and sensitive point-of-care testing. Chemistry 18 (16):4938–4945. doi:10.1002/chem.201102855

127. Shi CG, Shan X, Pan ZQ, Xu JJ, Lu C, Bao N, Gu HY (2012) Quantum dot (QD)-modified carbon tape electrodes for reproducible electrochemiluminescence (ECL) emission on a paper-based platform. Anal Chem 84(6):3033–3038. doi:10.1021/ac2033968

128. Zhang M, Ge L, Ge S, Yan M, Yu J, Huang J, Liu S (2013) Three-dimensional paper-based electrochemiluminescence device for simultaneous detection of Pb(2+) and Hg(2+) based on potential-control technique. Biosens Bioelectron 41:544–550. doi:10.1016/j.bios.2012.09.022

129. Mani V, Kadamisetty K, Malla S, Joshi AA, Rusling JF (2013) Paper-based electrochemiluminescent screening for genotoxic activity in the environment. Environ Sci Technol 47(4):1937–1944. doi:10.1021/es304426j

130. Yu J, Ge L, Huang J, Wang S, Ge S (2011) Microfluidic paper-based chemiluminescence biosensor for simultaneous determination of glucose and uric acid. Lab Chip 11 (7):1286–1291. doi:10.1039/c0lc00524j

131. Yu J, Wang S, Ge L, Ge S (2011) A novel chemiluminescence paper microfluidic biosensor based on enzymatic reaction for uric acid determination. Biosens Bioelectron 26 (7):3284–3289. doi:10.1016/j.bios.2010.12.044

132. Ge L, Wang S, Song X, Ge S, Yu J (2012) 3D origami-based multifunction-integrated immunodevice: low-cost and multiplexed sandwich chemiluminescence immunoassay on microfluidic paper-based analytical device. Lab Chip 12(17):3150–3158. doi:10.1039/c2lc40325k

133. Carrilho E, Phillips ST, Vella SJ, Martinez AW, Whitesides GM (2009) Paper microzone plates. Anal Chem 81(15):5990–5998. doi:10.1021/ac900847g

134. Ali MM, Aguirre SD, Xu YQ, Filipe CDM, Pelton R, Li YF (2009) Detection of DNA using bioactive paper strips. Chem Commun 43:6640–6642. doi:10.1039/B911559e

135. Allen PB, Arshad SA, Li B, Chen X, Ellington AD (2012) DNA circuits as amplifiers for the detection of nucleic acids on a paperfluidic platform. Lab Chip 12(16):2951–2958. doi:10.1039/c2lc40373k

136. Yildiz UH, Alagappan P, Liedberg B (2013) Naked eye detection of lung cancer associated miRNA by paper based biosensing platform. Anal Chem 85(2):820–824. doi:10.1021/ac3034008

137. Noor MO, Shahmuradyan A, Krull UJ (2013) Paper-based solid-phase nucleic acid hybridization assay using immobilized quantum dots as donors in fluorescence resonance energy transfer. Anal Chem 85(3):1860–1867. doi:10.1021/ac3032383

138. Miranda BS, Linares EM, Thalhammer S, Kubota LT (2013) Development of a disposable and highly sensitive paper-based immunosensor for early diagnosis of Asian soybean rust. Biosens Bioelectron 45C:123–128. doi:10.1016/j.bios.2013.01.048

139. Apilux A, Dungchai W, Siangproh W, Praphairaksit N, Henry CS, Chailapakul O (2010) Lab-on-paper with dual electrochemical/colorimetric determination of gold and iron. Anal Chem 82(5):1727–1732. doi:10.1021/ac902255s

140. Struss A, Pasini P, Ensor CM, Raut N, Daunert S (2010) Paper strip whole cell biosensors: a portable test for the semiquantitative detection of bacterial quorum signaling molecules. Anal Chem 82(11):4457–4463. doi:10.1021/ac100231a

141. Ellerbee AK, Phillips ST, Siegel AC, Mirica KA, Martinez AW, Striehl P, Jain N, Prentiss M, Whitesides GM (2009) Quantifying colorimetric assays in paper-based microfluidic devices by measuring the transmission of light through paper. Anal Chem 81 (20):8447–8452. doi:10.1021/ac901307q

142. Lee DS, Jeon BG, Ihm C, Park JK, Jung MY (2011) A simple and smart telemedicine device for developing regions: a pocket-sized colorimetric reader. Lab Chip 11(1):120–126. doi:10.1039/c0lc00209g

143. Shen L, Hagen JA, Papautsky I (2012) Point-of-care colorimetric detection with a smartphone. Lab Chip 12(21):4240–4243. doi:10.1039/c2lc40741h

144. Roche (2013) Chemstrip 10 MD package insert, cobas
145. Bakker E, Qin Y (2006) Electrochemical Sensors. Anal Chem 78(12):3965–3984. doi:10.1021/ac060637m
146. Chandler J, Gurmin T, Robinson N (2000) The place of gold in rapid tests. IVD Technol 6(2):37–59
147. Fu E, Liang T, Houghtaling J, Ramachandran S, Ramsey SA, Lutz B, Yager P (2011) Enhanced sensitivity of lateral flow tests using a two-dimensional paper network format. Anal Chem 83(20):7941–7946. doi:10.1021/ac201950g
148. Wang S, Ge L, Song X, Yu J, Ge S, Huang J, Zeng F (2012) Paper-based chemiluminescence ELISA: lab-on-paper based on chitosan modified paper device and wax-screen-printing. Biosens Bioelectron 31(1):212–218. doi:10.1016/j.bios.2011.10.019
149. Xue LL, Guo LH, Qiu B, Lin ZY, Chen GN (2009) Mechanism for inhibition of Ru(bpy)(3)2+/DBAE electrochemiluminescence system by dopamine. Electrochem Commun 11(8):1579–1582. doi:10.1016/j.elecom.2009.05.059
150. Dieterich K (1902) Testing-paper and method of making same. US Patent 691,249
151. Yagoda H (1937) Applications of confined spot tests in analytical chemistry: preliminary paper. Ind Eng Chem Anal Ed 9(2):79–82. doi:10.1021/ac50106a012
152. Herman Y (1938) Test paper. US Patent 2,129,754 A
153. Johnson JL (1967) Microchemical techniques in solving industrial problems. Microchem Acta 55(4):756–762. doi:10.1007/bf01224400
154. Deng S, Yetisen AK, Jiang K, Butt H (2014) Computational modelling of a graphene Fresnel lens on different substrates. RSC Adv 4(57):30050–30058. doi:10.1039/C4ra03991b
155. Kong X-T, Butt H, Yetisen AK, Kangwanwatana C, Montelongo Y, Deng S, Cruz Vasconcellos FD, Qasim MM, Wilkinson TD, Dai Q (2014) Enhanced reflection from inverse tapered nanocone arrays. Appl Phys Lett 105(5):053108. doi:10.1063/1.4892580
156. Kong XT, Khan AA, Kidambi PR, Deng S, Yetisen AK, Dlubak B, Hiralal P, Montelongo Y, Bowen J, Xavier S, Jiang K, Amarutunga GAJ, Hofmann S, Wilkinson TD, Dai Q, Butt H (2014) Graphene based ultra-thin flat lenses. (under review)
157. Vasconcellos FD, Yetisen AK, Montelongo Y, Butt H, Grigore A, Davidson CAB, Blyth J, Monteiro MJ, Wilkinson TD, Lowe CR (2014) Printable surface holograms via laser ablation. ACS Photonics 1(6):489–495. doi:10.1021/Ph400149m
158. Montelongo Y, Tenorio-Pearl JO, Williams C, Zhang S, Milne WI, Wilkinson TD (2014) Plasmonic nanoparticle scattering for color holograms. Proc Natl Acad Sci U S A 111(35):12679–12683. doi:10.1073/pnas.1405262111
159. Montelongo Y, Tenorio-Pearl JO, Milne WI, Wilkinson TD (2014) Polarization switchable diffraction based on subwavelength plasmonic nanoantennas. Nano Lett 14(1):294–298. doi:10.1021/nl4039967
160. Yetisen AK, Naydenova I, Vasconcellos FC, Blyth J, Lowe CR (2014) Holographic sensors: three-dimensional analyte-sensitive nanostructures and their applications. Chem Rev 114(20):10654–10696. doi:10.1021/CR500116a
161. Tsangarides CP, Yetisen AK, da Cruz Vasconcellos F, Montelongo Y, Qasim MM, Wilkinson TD, Lowe CR, Butt H (2014) Computational modelling and characterisation of nanoparticle-based tuneable photonic crystal sensors. RSC Adv 4(21):10454–10461. doi:10.1039/C3RA47984F
162. Yetisen AK, Butt H, da Cruz Vasconcellos F, Montelongo Y, Davidson CAB, Blyth J, Chan L, Carmody JB, Vignolini S, Steiner U, Baumberg JJ, Wilkinson TD, Lowe CR (2014) Light-directed writing of chemically tunable narrow-band holographic sensors. Adv Opt Mater 2(3):250–254. doi:10.1002/adom.201300375
163. Yetisen AK, Qasim MM, Nosheen S, Wilkinson TD, Lowe CR (2014) Pulsed laser writing of holographic nanosensors. J Mater Chem C 2(18):3569–3576. doi:10.1039/C3tc32507e
164. Yetisen AK, Montelongo Y, da Cruz Vasconcellos F, Martinez-Hurtado JL, Neupane S, Butt H, Qasim MM, Blyth J, Burling K, Carmody JB, Evans M, Wilkinson TD, Kubota LT, Monteiro MJ, Lowe CR (2014) Reusable, robust, and accurate laser-generated photonic nanosensor. Nano Lett 14(6):3587–3593. doi:10.1021/nl5012504
165. Yetisen AK, Montelongo Y, Qasim MM, Butt H, Wilkinson TD, Monteiro MJ, Lowe CR, Yun SH (2014) Nanocrystal bragg grating sensor for colorimetric detection of metal ions. (under review)
166. Yetisen AK, Martinez-Hurtado JL, da Cruz Vasconcellos F, Simsekler MC, Akram, Lowe CR (2014) The regulation of mobile medical applications. Lab Chip 14(5):833–840. doi:10.1039/c3lc51235e
167. Yetisen AK, Martinez-Hurtado JL, Garcia-Melendrez A, Vasconcellos FC, Lowe CR (2014) A smartphone algorithm with inter-phone repeatability for the analysis of colorimetric tests. Sens Actuators, B 196:156–160. doi:10.1016/j.snb.2014.01.077
168. Yetisen AK, Jiang L, Cooper JR, Qin Y, Palanivelu R, Zohar Y (2011) A microsystem-based assay for studying pollen tube guidance in plant reproduction. J Micromech Microeng 21 (5):054018. doi:10.1088/0960-1317/21/5/054018
169. Yetisen AK, Volpatti LR (2014) Patent protection and licensing in microfluidics. Lab Chip 14(13):2217–2225. doi:10.1039/c4lc00399c
170. Volpatti LR, Yetisen AK (2014) Commercialization of microfluidic devices. Trends Biotechnol 32(7):347–350. doi:10.1016/j.tibtech.2014.04.010
171. Farandos NM, Yetisen AK, Monteiro MJ, Lowe CR, Yun SH (2014) Contact lens sensors in ocular diagnostics. Adv Healthc Mater. doi:10.1002/adhm.201400504